Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-Start Antiplatelet Treatment in SICH
NCT04820972Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2021
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin in ischemic stroke, myocardial infarction (MI), venous thrombosis and 1 more (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: rate of intracranial hemorrhage at 90 days and rate of major adverse cardiac/cerebrovascular and peripheral vessel events at 90 days. Started May 2021; status: completed.
02
Drugs
aspirin
03
Conditions
ischemic strokemyocardial infarction (MI)venous thrombosisperipheral vascular disease (PVD)
Beyond the preview
Go deeper on NCT04820972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820972.